報價延遲最少15分鐘:2025/03/28 06:53 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
8.96 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-3.51/-2.16
|
|
企業價值
1.21B
|
| 資產負債 |
|
每股賬面淨值
2.75
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/03/28 06:53 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| 89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG). |